Researchers at Pfizer Release New Data on Vaccines (Development of a subunit vaccine for prevention of Clostridium difficile associated diseases: Biophysical characterization of toxoids A and B)
By a News Reporter-Staff News Editor at Vaccine Weekly -- New research on Immunization - Vaccines is the subject of a report. According to news reporting originating in Pearl River, New York, by NewsRx journalists, research stated, "Inactivation of bacterial toxins for use in human vaccines traditionally is achieved by treatment with formaldehyde. In contrast, the bivalent experimental vaccine for the prevention of infections (CDI) that is currently being evaluated in clinical trials was produced using a different strategy. toxins A and B were inactivated using site-directed mutagenesis and treatment with 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride/-hydroxysulfosuccinimide (EDC/NHS)."
The news reporters obtained a quote from the research from Pfizer, "In the present work we investigate the effect of genetic and chemical modifications on the structure of inactivated toxins (toxoids) A and B. The far-UV circular dichroism (CD) spectra of wild type toxins, mutated toxins, and EDC/NHS-inactivated toxoids reveal that the secondary structure of all proteins is very similar. The near-UV CD spectra show that aromatic residues of all proteins are in a unique asymmetric environment, indicative of well-defined tertiary structure. These results along with the fluorescence emission maxima of 335?nm observed for all proteins suggest that the tertiary structure of toxoids A and B is preserved as well. Analytical ultracentrifugation data demonstrate that all proteins are predominantly monomeric with small fractions of higher molecular weight oligomeric species present in toxoids A and B. Differential scanning calorimetry data reveal that genetic mutations induce thermal destabilization of protein structures. Subsequent treatment with EDC/NHS results either in a minimal (1??C) increase of apparent thermostability (toxoid B) or no change at all (toxoid A)."
According to the news reporters, the research concluded: "Therefore, our two-step inactivation strategy is an effective approach for the preparation of non-toxic proteins maintaining native-like structure and conformation."
For more information on this research see: Development of a subunit vaccine for prevention of Clostridium difficile associated diseases: Biophysical characterization of toxoids A and B. Biochemistry and Biophysics Reports, 2017;9():193-202 (see also Immunization - Vaccines).
Our news correspondents report that additional information may be obtained by contacting A. Gribenko, Pfizer Vaccine Research and Development, 401 N Middletown Road, Pearl River, NY 10965, United States. Additional authors for this research include E. Severina, M.K. Sidhu, K.U. Jansen, B.A. Green and Y.V Matsuka.
The direct object identifier (DOI) for that additional information is: http://dx.doi.org/10.1016/j.bbrep.2016.12.015. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
Keywords for this news article include: New York, Genetics, Vaccines, Pearl River, Immunization, United States, Biological Products, Risk and Prevention, Clostridium difficile, Gram Positive Bacteria, North and Central America, Gram Positive Endospore Forming Rods, Gram Positive Endospore Forming Bacteria.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC